J Cancer 2017; 8(14):2846-2853. doi:10.7150/jca.19897 This issue Cite

Research Paper

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Xiyong Wang1, 2, Xiaoli Zhu1, 2, Hongming Zhang1, 2, Xiaobo Fan1, Xiulei Xue1, Yan Chen1, Chenbo Ding1, Jianwen Zhao1, Guoqiu Wu1, 3✉

1. Medical school of Southeast University, Nanjing 210009, China;
2. Department of Respiratory Medicine, Zhongda Hospital, Southeast University, Nanjing, 210009, China;
3. Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing, 210009, China.

Citation:
Wang X, Zhu X, Zhang H, Fan X, Xue X, Chen Y, Ding C, Zhao J, Wu G. ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. J Cancer 2017; 8(14):2846-2853. doi:10.7150/jca.19897. https://www.jcancer.org/v08p2846.htm
Other styles

File import instruction

Abstract

Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC).

Methods: The relative complementary DNA (cDNA) quantification for ERCC1_202 was conducted using a fluorescence-based, real-time detection method and β-actin was used as a reference gene.

Results: A strong correlation was observed between ERCC1_202 mRNA and ERCC1 mRNA levels in NSCLC cells (P < 0.001). 28 patients completed this research. Our results implied that as ERCC1_202 levels increased, the risk of progression (HR = 4.296, P = 0.011) and death (HR = 6.503, P = 0.001) increased. At multivariate analysis, high expression of ERCC1_202 was shown to be an independent predictive factor for time to progression (P = 0.047), and progression-free survival (P = 0.014). However, the high expression of ERCC1_202 was not an independent predictive factor for response (P = 0.324).

Conclusions: This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the expression of ERCC1_202.

Keywords: non-small cell lung cancer, ERCC-1, 202 isoform, Cisplatin, resistance.


Citation styles

APA
Wang, X., Zhu, X., Zhang, H., Fan, X., Xue, X., Chen, Y., Ding, C., Zhao, J., Wu, G. (2017). ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Journal of Cancer, 8(14), 2846-2853. https://doi.org/10.7150/jca.19897.

ACS
Wang, X.; Zhu, X.; Zhang, H.; Fan, X.; Xue, X.; Chen, Y.; Ding, C.; Zhao, J.; Wu, G. ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. J. Cancer 2017, 8 (14), 2846-2853. DOI: 10.7150/jca.19897.

NLM
Wang X, Zhu X, Zhang H, Fan X, Xue X, Chen Y, Ding C, Zhao J, Wu G. ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. J Cancer 2017; 8(14):2846-2853. doi:10.7150/jca.19897. https://www.jcancer.org/v08p2846.htm

CSE
Wang X, Zhu X, Zhang H, Fan X, Xue X, Chen Y, Ding C, Zhao J, Wu G. 2017. ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. J Cancer. 8(14):2846-2853.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image